Zanidatamab plus chemotherapy as first-line treatment for patients with HER2-positive advanced gastro-oesophageal adenocarcinoma: primary results of a multicentre, single-arm, phase 2 study. - Elimova, Elena; Ajani, Jaffer; Burris, Howard; Denlinger, Crystal S; Iqbal, Syma; Kang, Yoon-Koo; Kim, Jwa Hoon; Lee, Keun-Wook; Lin, Bruce; Mehta, Rutika; Oh, Do-Youn; Rha, Sun Young; et al. (Lancet Oncology, 2025)